Testosterone Patch: How It Compares to Injections, Pellets, and Other TRT Options

How the Testosterone Patch Works

The Androderm transdermal system releases testosterone through a rate-controlling membrane directly into dermal capillaries over a 24-hour period. Applied nightly, the patch produces peak serum testosterone concentrations between 3 and 12 hours after application, which aligns with the body's natural diurnal hormone pattern [1]. This is a meaningful pharmacokinetic advantage.

The Endocrine Society's 2018 clinical practice guideline recommends maintaining serum testosterone between 300 and 1,000 ng/dL during treatment, and transdermal formulations are listed as a first-line option alongside intramuscular injections [2]. A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that Androderm 5 mg patches produced mean steady-state testosterone levels of 532 ± 135 ng/dL in hypogonadal men, with morning peaks averaging 742 ng/dL [3]. Those values fall squarely within the physiologic range for healthy males aged 19 to 39.

Patches are applied to clean, dry, intact skin on the back, abdomen, upper arms, or thighs. Rotation of the application site is necessary because repeated use on the same area increases irritation risk. The prescribing information specifies that sites should not be reused for at least 7 days [1].

Testosterone Patch vs. Injectable Testosterone

Injectable testosterone esters remain the most prescribed TRT delivery system in the United States, and three esters dominate clinical practice: cypionate, enanthate, and propionate. Each differs from the patch in pharmacokinetics, injection frequency, and patient experience.

Testosterone cypionate carries an 8-carbon ester chain that slows absorption from the intramuscular depot, producing a half-life of approximately 8 days. Standard dosing is 100 to 200 mg every 7 to 14 days [4]. Cypionate accounts for the majority of U.S. prescriptions partly because it is manufactured domestically and available as a low-cost generic (Depo-Testosterone). A retrospective cohort study of 3,422 men starting TRT found that 76% were initiated on injectable cypionate rather than gels or patches [5].

Testosterone enanthate has a 7-carbon ester and a slightly shorter half-life of approximately 4.5 days, though clinical dosing protocols are virtually identical to cypionate: 100 to 200 mg intramuscularly every 7 to 14 days [4]. The European Medicines Agency lists enanthate as the preferred injectable ester across EU member states, while cypionate dominates North American formularies [6]. A head-to-head crossover trial (N=39) showed no statistically significant difference in trough testosterone levels, hematocrit rise, or patient-reported symptom scores between the two esters at equivalent doses [7].

Testosterone propionate is the shortest-acting injectable, with a half-life of roughly 0.8 days. It requires injection every 2 to 3 days to maintain stable levels, making it impractical for most TRT patients. Propionate does appear in compounded blends and remains useful in short-duration clinical protocols, but the Endocrine Society does not recommend it as a standalone maintenance ester [2].

The patch's primary advantage over all three injectables is hormonal stability. Injectable esters produce supraphysiologic peaks 24 to 48 hours after injection, followed by a trough before the next dose. A crossover study published in Clinical Endocrinology measured a coefficient of variation of 42% in serum testosterone across a single cypionate injection cycle, compared to 18% with daily transdermal delivery [8]. That reduced fluctuation may matter for mood, energy, and erythrocytosis risk.

Testosterone Pellets: The Longest-Acting Option

Testosterone pellets (Testopel) are crystalline implants inserted subcutaneously in the hip or gluteal fat pad during a brief office procedure. Each pellet contains 75 mg of fused crystalline testosterone, and most patients receive 6 to 12 pellets (450 to 900 mg total) every 3 to 6 months [9].

Pellets offer the longest dosing interval of any TRT formulation. A prospective study of 380 hypogonadal men receiving Testopel implants found that 85% maintained serum testosterone above 400 ng/dL at 4 months post-insertion [10]. The trade-off is that dose adjustments are impossible once pellets are placed. If levels run too high, the patient must wait for the pellets to dissolve. Extrusion (pellets working their way out through the skin) occurs in 5% to 12% of insertions according to published case series [10].

Compared to the patch, pellets eliminate daily compliance entirely. But the patch allows day-to-day dose titration by changing patch strength (2 mg vs. 4 mg vs. 6 mg), an option that no implantable or depot injection can match. For men who need precise dose control because of polycythemia risk or fluctuating symptoms, transdermal delivery has a clear edge.

Clinical Efficacy and Outcomes Data

The TTrials (Testosterone Trials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, provides the strongest evidence base for transdermal testosterone's benefits [11]. Men randomized to 1% testosterone gel (a related transdermal formulation) for 12 months showed statistically significant improvements in sexual function (P<0.001), walking distance on the 6-minute walk test (P=0.03), and hemoglobin levels (P<0.001) compared to placebo [11].

While the TTrials used gel rather than patches, both deliver testosterone transdermally. The TRAVERSE trial (N=5,246), the largest cardiovascular safety trial of TRT to date, similarly used 1.62% transdermal gel and found no increased risk of major adverse cardiovascular events (MACE) over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [12]. The FDA updated testosterone labeling in 2015 to require a cardiovascular warning, but TRAVERSE data published in 2023 prompted re-evaluation of that risk signal [12].

Dr. Shalender Bhasin, principal investigator of the TTrials and professor of medicine at Harvard Medical School, stated: "Testosterone treatment in older men with low testosterone improved sexual function, physical function, and vitality, but clinicians must weigh benefits against the increase in coronary artery plaque volume that we observed" [11].

The Endocrine Society guideline co-chair Dr. Bhasin also noted in the 2018 guideline: "We recommend testosterone therapy for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [2].

Side Effects and Skin Reactions

The most frequently reported adverse event with testosterone patches is application site reaction. In the key Androderm registration trial, 37% of participants experienced some degree of erythema, pruritus, or vesiculation at the patch site [1]. That figure is notably higher than the skin irritation rate with testosterone gels, which ranges from 5% to 15% depending on formulation [13].

Systemic side effects shared by all TRT formulations include:

• Erythrocytosis. Hematocrit elevation above 54% occurs in 3% to 18% of TRT users regardless of delivery route. The patch may carry lower risk than injections because it avoids supraphysiologic peaks. A VA database study (N=21,467) found that men on injectable testosterone had a 2.2-fold higher rate of polycythemia-related phlebotomy than those on transdermal formulations [14].
• Acne and oily skin. Reported in approximately 8% of patch users in post-marketing surveillance [1].
• Sleep apnea. TRT can worsen pre-existing obstructive sleep apnea, though the Endocrine Society notes the evidence is limited to case reports and small series [2].
• Fertility suppression. All exogenous testosterone suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary-gonadal axis. Men desiring fertility should not use any testosterone formulation without concurrent gonadotropin therapy [2].

Patients who develop persistent skin reactions to the patch may pretreat the site with 0.1% triamcinolone acetonide cream. A small crossover trial (N=20) showed this reduced moderate-to-severe reactions from 42% to 12% without affecting testosterone absorption [15].

Who Should Consider the Testosterone Patch

The patch fits a specific clinical profile best. Men who want steady, physiologic hormone levels without injections. Men who prefer daily dose flexibility over the long intervals of pellets or undecanoate. Men who tolerate adhesive medical products without significant skin sensitivity.

The patch is less suitable for men with dermatitis, psoriasis, or excessive body hair at viable application sites, as these conditions reduce adhesion and absorption. Men with BMI above 35 may also experience suboptimal absorption because of increased subcutaneous fat thickness at patch sites, though formal pharmacokinetic data in this population remain sparse [13].

For men who fail the patch due to skin irritation, the two most common step-therapy alternatives are testosterone gel (AndroGel, Testim, Vogelxo) and injectable cypionate. Nasal testosterone (Natesto, 5.5 mg per nostril three times daily) is another needle-free option approved in 2014, though its short duration of action and three-times-daily dosing schedule limit adoption [16].

Cost and Insurance Considerations

Brand-name Androderm patches carry an average wholesale price (AWP) of approximately $650 to $900 per month for the 4 mg daily dose, depending on pharmacy and region. Generic transdermal testosterone patches became available in 2018 and brought the cash price down to roughly $150 to $300 per month at major pharmacy chains.

By comparison, generic testosterone cypionate 200 mg/mL (10 mL vial) costs approximately $30 to $75 for a 2- to 3-month supply, making injectables the most cost-effective TRT option by a wide margin [4]. Testosterone pellet insertion procedures range from $500 to $1,200 per session (including the office procedure fee), with sessions needed every 3 to 6 months.

Most commercial insurance plans and Medicare Part D cover Androderm or its generic equivalent with prior authorization requiring two documented morning serum testosterone levels below 300 ng/dL and signs or symptoms of hypogonadism. The AUA/Endocrine Society diagnostic threshold is a total testosterone below 300 ng/dL drawn between 7 and 11 AM on two separate occasions [2].

Monitoring on the Testosterone Patch

The Endocrine Society recommends checking serum testosterone 3 to 12 hours after patch application (to capture the absorption peak) at 3 months, 6 months, and then annually [2]. Hematocrit should be measured at baseline, at 3 to 6 months, and annually thereafter. A hematocrit above 54% should prompt dose reduction or temporary discontinuation.

PSA should be measured at baseline and at 3 to 6 months if the patient is over 40 and has agreed to prostate cancer screening after shared decision-making. Lipid panels and liver function tests at baseline and 12 months round out the standard monitoring protocol [2].

Bone mineral density testing via DXA scan is recommended at baseline and after 1 to 2 years for men with osteoporosis or prior fragility fractures, as TRT has been shown to improve lumbar spine BMD by 3.7% over 12 months in the TTrials bone substudy [17].